CJC-1295 + Ipamorelin vs Sermorelin

CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin is one preparation holding two separate compounds, a GHRH analogue and a growth hormone secretagogue. Each component has a published literature of its own and a profile of its own on this site. The blend itself has none. No controlled study of the two given together was located. The nearest published work is a 2013 analytical paper describing a method that detects both, among seven peptides, in horse plasma, and a set of recent review articles that list them side by side. Every citation here is attributed to one component or the other.

Sermorelin

Sermorelin is a synthetic 29-residue peptide reproducing the N-terminal segment of human growth hormone-releasing hormone (GHRH). Native GHRH has 44 residues, and the 1–29 segment, amidated at its C-terminus as here, is reported to retain the receptor activity of the full hormone. Like native GHRH, it is cut quickly by plasma enzymes including dipeptidyl peptidase-4, a property that later analogues such as tesamorelin were modified to avoid. Research on it has centred on growth hormone release from the anterior pituitary, including human physiology studies, many of them decades old, alongside animal and cell work. Recent literature on sermorelin itself is sparse beside that on newer GHRH analogues.

How CJC-1295 + Ipamorelin acts

The two components act at different receptors. CJC-1295 is a modified analogue of growth hormone-releasing hormone; a 2006 randomised, placebo-controlled trial in healthy adults reported sustained rises in growth hormone and IGF-1 after a long-acting form of it. Ipamorelin is a pentapeptide that releases growth hormone through the growth hormone secretagogue receptor rather than the GHRH receptor, and its 1998 description in rat pituitary cells, rats and swine reported release without the rise in ACTH and cortisol seen with GHRP-6 and GHRP-2. Nothing published describes what the two do together.

How Sermorelin acts

Sermorelin binds the GHRH receptor, a class B G-protein-coupled receptor on somatotroph cells of the anterior pituitary. Receptor activation has been reported to raise cyclic AMP and activate protein kinase A and the transcription factor CREB, which is linked to transcription of the growth hormone gene as well as to release of stored hormone. Because it acts upstream of the pituitary, the growth hormone released stays subject to inhibition by somatostatin and to negative feedback from IGF-1. This is the main pharmacological difference between GHRH analogues and growth hormone itself.

The records side by side

• Type: CJC-1295 + Ipamorelin, Two-peptide blend; Sermorelin, GHRH analog (growth hormone secretagogue)
• Length: CJC-1295 + Ipamorelin, not recorded; Sermorelin, 29 amino acids
• Molecular weight: CJC-1295 + Ipamorelin, not recorded; Sermorelin, 3357.9 g/mol
• Molecular formula: CJC-1295 + Ipamorelin, not recorded; Sermorelin, C149H246N44O42S

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.